Complement and complement regulatory proteins as potential molecular targets for vascular diseases

Current Pharmaceutical Design

Volumn 10, Issue 2, 2004, Pages 203-211

  Acosta, Juan ^b,c   Qin, Xuebin ^a,b   Halperin, Jose ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; CD59 ANTIGEN; COBROTOXIN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR D; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPSTATIN; CYTOKINE; DECAY ACCELERATING FACTOR; GROWTH FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MEMBRANE COFACTOR PROTEIN; UNCLASSIFIED DRUG;

ANAPHYLACTOID PURPURA; ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CAPILLARY LEAK SYNDROME; CELL MEMBRANE; CELL PROLIFERATION; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DERMATOMYOSITIS; DIABETES MELLITUS; ENDOTHELIUM CELL; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERACUTE GRAFT REJECTION; INFLAMMATION; ISCHEMIA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSGENIC ANIMAL; VASCULAR DISEASE; VASCULITIS;

ANIMALS; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; RECEPTORS, COMPLEMENT; VASCULAR DISEASES; VASCULITIS;

EID: 0346656612     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453441     Document Type: Review

References (124)

1. Morgan BP, Harris CL. Complement Regulatory Proteins. London: Academic Press; 1999.
2. Morgan BP. Complement: Clinical Aspects and Relevance to Disease. London: Academic Press; 1990.
3. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-66.
4. Podack ER, Tschopp J. Membrane attack by complement. Mol Immunol 1984; 21: 589-603.
5. Tschopp J, Engel A, Podack ER. Molecular weight of poly(C9). 12 to 18 C9 molecules form the transmembrane channel of complement. J Biol Chem 1984; 259: 1922-8.
6. Podack ER. Molecular composition of the tubular structure of the membrane attack complex of complement. J Biol Chem 1984; 259: 8641-7.
7. Mayer MM. Complement: historical perspective and some current issues. Complement 1984; 1: 2-26.
8. Halperin JA, Taratuska A, Rynkiewicz M, Nicholson-Weller A. Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood 1993; 81: 200-5.
9. Acosta JA, Benzaquen LR, Goldstein DJ, Tosteson MT, Halperin JA. The transient pore formed by homologous terminal complement complexes functions as a bidirectional route for the transport of autocrine and paracrine signals across human cell membranes. Mol Med 1996; 2: 755-65.
10. Halperin JA, Brugnara C, Nicholson-Weller A. Ca2+-activated K+ efflux limits complement-mediated lysis of human erythrocytes. J Clin Invest 1989; 83: 1466-71.
11. Nicholson-Weller A, Halperin JA. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol Res 1993; 12: 244-57.
12. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994; 179: 985-92.
13. Halperin JA, Taratuska A, Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 1993; 91: 1974-8.
14. Shankland SJ, Pippin JW, Couser WG. Complement (C5b-9) induces glomerular epithelial cell DNA synthesis but not proliferation in vitro. Kidney Int 1999; 56: 538-48.
15. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in the atherosclerotic lesion formation. Arterioscler. Thromb Vasc Biol 1996; 16: 673-677.
16. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264: 9053-60.
17. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-14.
18. Marks RM, Todd RF III, Ward Pa. Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature 1989; 339: 314-317.
19. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J. Exp. Med. 1995; 182: 1807-1814.
20. Cybulsky AV, Bonventre JV, Quigg RJ, Lieberthal W, Salant DJ. Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial injury. Kidney Int 1990; 38: 803-11.
21. Carney DF, Lang TJ, Shin ML. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol 1990; 145: 623-9.
22. Niculescu F, Rus H. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res 2001; 24: 191-9.
23. Collard CD, Agah A, Reenstra W, Buras J, Stahl GL. Endothelial nuclear factor-kappaB translocation and vascular cell adhesion molecule-1 induction by complement: inhibition with anti-human C5 therapy or cGMP analogues. Arterioscler Thromb Vasc Biol 1999; 19: 2623-9.
24. Viedt C, Hansch GM, Brandes RP, Kohler W, Kreuzer J. The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappaB and AP-1 [In Process Citation]. FASEB J 2000; 14: 2370-2.
25. Nicholson-Weller A, March JP, Rosen CE, Spicer DB, Austen KF. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood 1985; 65: 1237-44.
26. Medof ME, Lublin DM, Holers VM, Ayers DJ, Getty RR, Leykam JF, et al. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci USA 1987; 84: 2007-11.
27. Davitz MA, Low MG, Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med 1986; 163: 1150-61.
28. Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 1996; 3: 101-10.
29. Halperin JA, Nicholson-Weller A. Paroxysmal nocturnal hemoglobinuria. A complement-mediated disease. Complement Inflamm 1989; 6: 65-72.
30. Parker CJ. Molecular basis of paroxysmal nocturnal hemoglobinuria. Stem Cells 1996; 14: 396-411.
31. Shats-Tseytlina EA, Nair CH, Dhall DP. Complement activation: a new participant in the modulation of fibrin gel characteristics and the progression of atherosclerosis? Blood Coagul Fibrinolysis 1994; 5: 529-35.
32. Seifert PS, Kazatchkine MD. The complement system in atherosclerosis. Atherosclerosis 1988; 73: 91-104.
33. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol 1994; 34: 17-40.
34. Stahl GL, Xu Y, Hao L, Miller M, Buras JA, Fung M, et al. Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 2003; 162: 449-55.
35. Tada T, Okada H, Okada N, Tateyama H, Suzuki H, Takahashi Y, et al. Membrane attack complex of complement and 20 KDA homologous restriction factor (CD59) in myocardial infarction. Virchows Arch 1997; 430: 327-332.
36. Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, Angarita L, et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci USA 2000; 97: 5450-5.
37. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 2002; 51: 3499-504.
38. Rosoklija GB, Dwork AJ, Younger DS, Karlikaya G, Latov N, Hays AP. Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol (Berl) 2000; 99: 55-62.
39. Gulati P, Guc D, Lemercier C, Lappin D, Whaley K. Expression of the components and regulatory proteins of the classical pathway of complement in normal and diseased synovium. Rheumatol Int 1994; 14: 13-9.
40. Carney DF, Lang TJ, Shin ML. Multiple signal messengers generated by terminal complement complexes and their role in terminal complexes elimination. J Immunol 1990; 145: 621-629.
41. Langeggen H, Berge KE, Johnson E, Hetland G. Human umbilical vein endothelial cells express complement receptor 1 (CD35) and complement receptor 4 (CD11c/CD18) in vitro. Inflammation 2002; 26: 103-10.
42. Mason JC, Lidington EA, Ahmad SR, Haskard DO. bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. Am J Physiol Cell Physiol 2002; 282: C578-87.
43. Mason JC, Lidington EA, Yarwood H, Lublin DM, Haskard DO. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum 2001; 44: 138-50.
44. Tsuji S, Kaji K, Nagasawa S. Decay-accelerating factor on human umbilical vein endothelial cells. Its histamine-induced expression and spontaneous rapid shedding from the cell surface. J Immunol 1994; 152: 1404-10.
45. Lidington EA, Haskard DO, Mason JC. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 2000; 96: 2784-92.
46. Vakeva A, Meri S. Complement activation and regulator expression after anoxic injury of human endothelial cells. Apmis 1998; 106: 1149-56.
47. Collard CD, Montalto MC, Reenstra WR, Buras JA, Stahl GL. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol 2001; 159: 1045-54.
48. Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 2000; 156: 1549-56.
49. Morgan BP. Complement regulatory molecules: application to therapy and transplantation. Immunol Today 1995; 16: 257-9.
50. Hamilton KK, Ji Z, Rollins S, Stewart BH, Sims PJ. Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59. Blood 1990; 76: 2572-7.
51. Holguin MH, Martin CB, Eggett T, Parker CJ. Analysis of the gene that encodes the complement regulatory protein, membrane inhibitor of reactive lysis (CD59). Identification of an alternatively spliced exon and characterization of the transcriptional regulatory regions of the promoter. J Immunol 1996; 157: 1659-68.
52. Petranka JG, Fleenor DE, Sykes K, Kaufman RE, Rosse WF. Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. Proc Natl Acad Sci USA 1992; 89: 7876-9.
53. Lin RC, Herman J, Henry L, Daniels GL. A family showing inheritance of the Inab phenotype. Transfusion 1988; 28: 427-9.
54. Telen MJ, Green AM. The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood 1989; 74: 437-41.
55. Reid ME, Mallinson G, Sim RB, Poole J, Pausch V, Merry AH, et al. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Blood 1991; 78: 3291-7.
56. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song W-C. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci USA 1999; 96: 628-633.
57. Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990; 323: 1184-9.
58. Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ, Morgan BP. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 2001; 98: 442-9.
59. Qin X, Miwa T, Aktas H, Gao M, Lee C, Qian YM, et al. Genomic structure, functional comparison, and tissue distribution of mouse Cd59a and Cd59b. Mamm Genome 2001; 12: 582-9.
60. Qian YM, Qin X, Miwa T, Sun X, Halperin JA, Song WC. Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59. J Immunol 2000; 165: 2528-34.
61. Qin X, Krumrei N, Grubissich L, Dobarro M, Aktas H, Perez G, et al. Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity 2003; 18: 217-27.
62. Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 108: 470-9.
63. Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993; 82: 1192-6.
64. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94: 110-7.
65. Fletcher CM, Harrison RA, Lachmarm PJ, Neuhaus D. Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure 1994; 2: 185-99.
66. Bodian DL, Davis SJ, Morgan BP, Rushmere NK. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med 1997; 185: 507-16.
67. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1999; 48: 1454-8.
68. Falk RJ, Scheinman JI, Mauer SM, Michael AF. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 1983; 32 Suppl 2: 34-9.
69. Falk RJ, Sisson SP, Dalmasso AP, Kim Y, Michael AF, Vernier RL. Ultrastructural localization of the membrane attack complex of complement in human renal tissues. Am J Kidney Dis 1987; 9: 121-8.
70. Weiss JS, Sang DN, Albert DM. Immunofluorescent characteristics of the diabetic cornea. Cornea 1990; 9: 131-138.
71. Dalmasso AP. The complement system in xenotransplantation. Immunopharmacology 1992; 24: 149-60.
72. Brauer RB, Baldwin WM 3rd, Daha MR, Pruitt SK, Sanfilippo F. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993; 151: 7240-8.
73. Leventhal JR, Dalmasso AP, Cromwell JW, Platt JL, Manivel CJ, Bolman RM 3rd, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857-65; discussion 865-6.
74. Pruitt SK, Kirk AD, Bollinger RR, Marsh HC Jr, Collins BH, Levin JL, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363-70.
75. McCurry KR, Kooyman DL, Alvarado CG, Cotterell AH, Martin MJ, Logan JS, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1995; 1: 423-7.
76. Cowan PJ, Shinkel TA, Witort EJ, Barlow H, Pearse MJ, d'Apice AJ. Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Transplantation 1996; 62: 155-60.
77. Cowan PJ, Somerville CA, Shinkel TA, Katerelos M, Aminian A, Romanella M, et al. High-level endothelial expression of human CD59 prolongs heart function in an ex vivo model of xenograft rejection. Transplantation 1998; 65: 826-31.
78. Rougier N, Kazatchkine MD, Rougier JP, Fremeaux-Bacchi V, Blouin J, Deschenes G, et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9: 2318-26.
79. Levy M, Halbwachs-Mecarelli L, Gubler MC, Kohout G, Bensenouci A, Niaudet P, et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986; 30: 949-56.
80. Hogasen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995; 95: 1054-61.
81. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31: 424-8.
82. Hanafusa N, Sogabe H, Yamada K, Wada T, Fujita T, Nangaku M. Contribution of genetically engineered animals to the analyses of complement in the pathogenesis of nephritis. Nephrol Dial Transplant 2002; 17 Suppl 9: 34-6.
83. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, et al. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol 1998; 9: 590-7.
84. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
85. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol 1999; 36: 949-55.
86. Hansson GK, Holm J, Kral JG. Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta Pathol Microbiol Immunol Scand [A] 1984; 92: 429-35.
87. Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985; 57: 163-77.
88. Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 1989; 60: 747-54.
89. Schmiedt W, Kinscherf R, Deigner HP, Kamencic H, Nauen O, Kilo J, et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18: 1790-1795.
90. Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, et al. Influence of C3 deficiency on atherosclerosis. Circulation 2002; 105: 3025-31.
91. Patel S, Thelander EM, Hernandez M, Montenegro J, Hassing H, Burton C, et al. ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun 2001; 286: 164-70.
92. Langeggen H, Pausa M, Johnson E, Casarsa C, Tedesco F. The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 2000; 121: 69-76.
93. Langeggen H, Berge KE, Macor P, Fischetti F, Tedesco F, Hetland G, et al. Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. Apmis 2001; 109: 73-8.
94. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582-7.
95. Wurzner R. Modulation of complement membrane attack by local C7 synthesis. Clin Exp Immunol 2000; 121: 8-10.
96. Marsh JE, Zhou W, Sacks SH. Local tissue complement synthesis -fine tuning a blunt instrument. Arch Immunol Ther Exp (Warsz) 2001; 49 Suppl 1: S41-6.
97. Esterbauer H, Krempler F, Oberkofler H, Patsch W. The complement system: a pathway linking host defence and adipocyte biology. Eur J Clin Invest 1999; 29: 653-6.
98. Korthuis RJ, Smith JK, Carden DL. Hypoxic reperfusion attenuates postischemic microvascular injury. Am J Physiol Heart Circ Physiol 1989; 256: H315-319.
99. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105: 1363-1371.
100. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146-151.
101. Ikai M, Itoh M, Job T, Yokoyama Y, Okada N, Okada H. Complement plays an essential role in shock following intestinal ischaemia in rats. Clin Exp Immunol 1996; 106: 156-9.
102. Eppinger M, Deeb G, Bolling S, Ward P. Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol 1997; 150: 1773-1784.
103. Weiser M, Williams J, Moore F Jr, Kobzik L, Ma M, Hechtman H, et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996; 183: 2343-2348.
104. Vakeva A, Lehto T, Takala A, Meri S. Detection of a soluble form of the complement membrane attack complex inhibitor CD59 in plasma after acute myocardial infarction. Scand J Immumol 2000; 52: 411-4.
105. Vakeva A, Laurila P, Meri S. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition ih myocardial infarction. Lab Invest 1992; 67: 608-16.
106. Ren G, Hack BK, Minto AW, Cunningham PN, Alexander JJ, Haas M, et al. A complement-dependent model of thrombotic thrombocytopenic purpura induced by antibodies reactive with endothelial cells. Clin Immunol 2002; 103: 43-53.
107. Goncalves FG, Chimelli L, Sallum AM, Marie SK, Kiss MH, Ferriani VP. Immunohistological analysis of CD59 and membrane attack complex of complement in muscle in juvenile dermatomyositis. J Rheumatol 2002; 29: 1301-7.
108. Kawana S, Shen GH, Kobayashi Y, Nishiyama S. Membrane attack complex of complement in Henoch-Schonlein purpura skin and nephritis. Arch Dermatol Res 1990; 282: 183-7.
109. Cines DB, Lyss AP, Reeber M, Bina M, DeHoratius RJ. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin Invest 1984; 73: 611-25.
110. Navratil JS, Korb LC, Ahearn JM. Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Immunopharmacology 1999; 42: 47-52.
111. Tomooka K. [Serum complement levels in patients with rheumatoid arthritis and vasculitis]. Fukuoka Igaku Zasshi 1989; 80: 456-66.
112. Tripathy NK, Upadhyaya S, Sinha N, Nityanand S. Complement and cell mediated cytotoxicity by antiendothelial cell antibodies in Takayasu's arteritis. J Rheumatol 2001; 28: 805-8.
113. Asghar SS, Pasch MC. Therapeutic inhibition of the complement system. Y2K update. Front Biosci 2000; 5: E63-81.
114. Monsinjon T, Richard V, Fontaine M. Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement. Fundam Clin Pharmacol 2001; 15: 293-306.
115. Kirschfink M. Targeting complement in therapy. Immunol Rev 2001; 180: 177-89.
116. Heller A, Koch T. The complement system: an old story or target of new therapeutic approaches?. Anasthesiol Intensivmed Notfallmed Schmerzther 2000; 35: 207-13.
117. Kirschfink M. Controlling the complement system in inflammation. Immunopharmacology 1997; 38: 51-62.
118. Fiane AE, Mollnes TE, Videm V, Hovig T, Hogasen K, Mellbye OJ, et al. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation 1999; 6: 52-65.
119. Morikis D, Assa-Munt N, Sabu A, Lambris JD. Solution structure of Compstatin, a potent complement inhibitor. Protein Sci 1998; 7: 619-27.
120. Sahu A, Morikis D, Lambris JD. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol 2003; 39: 557-66.
121. Dalmasso AP, Benson BA, Johnson JS, Lancto C, Abrahamsen MS. Resistance against the membrane attack complex of complement induced in porcine endothelial cells with a Gal alpha(1-3)Gat binding lectin: up-regulation of CD59 expression. J Immunol 2000; 164: 3764-73.
122. Alarcon de la Lastra C, Barranco MD, Motilva V, Hefferias JM. Mediterranean diet and health: biological importance of olive oil. Curr Pharm Design 2001; 7(10): 933-50.
123. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Design 2002; 8(3): 155-66.
124. Yoshida M, Loo JA, Lepleya RA. Proteomics as a tool in the pharmaceutical drug design process. Curr Pharm Design 2001; 7(4): 291-310.